Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis

Abstract

Aims

Glucagon is used to resolve severe hypoglycemia in unconscious patients with diabetes, requiring third-party assistance. A few studies have shown that intranasal (IN) glucagon causes resolution of hypoglycemia in insulin-treated patients with type 1 (T1DM) diabetes. This systematic review and meta-analysis updates the comparison of the effectiveness of IN glucagon with injected intramuscular/subcutaneous (IM/SC) glucagon in treatment of hypoglycemia in T1DM.

Methods

Controlled randomized studies were considered; eight studies, published in English, were included in a meta-analysis (random-effects model). Intervention effect (resolution of hypoglycemia) was expressed as odds ratio (OR), with 95% confidence intervals. Meta-regression was employed to correlate the effect with size of studies, age of patients, basal blood glucose levels.

Results

In a total of 467 treatments in 269 patients with IN and IM/SC glucagon, the OR IN versus IM/SC was 0.61 (CI 0.13–2.82); since four of eight studies showed 100% effectiveness, a simulation was made with 1 failure for each treatment; in this simulation analysis, the OR was 0.80 (95% CI 0.28–2.32). Heterogeneity was low and not statistically significant. Publication bias was absent, and quality of papers was high. At meta-regression, no correlation was found between the effect and number of patients in each study, age of patients, basal blood glucose levels. No study formally compared IN versus IM/SC in unconscious patients.

Conclusions

This meta-analysis indicates that in conscious T1DM patients IN glucagon and IM/SC glucagon are equally effective in resolution of hypoglycemia.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Cryer P (2012) Hypoglycaemia in diabetes: pathophysiology, prevalence and prevention, 2nd edn. American Diabetes Association, Alexandria

  2. 2.

    UK Hypoglycaemia Study Group (2007) Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50:1140–1147

  3. 3.

    Centers for Disease Control and Prevention (CDC) (2011) National diabetes fact sheet: national estimates, general information on diabetes, prediabetes in the United States. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta

  4. 4.

    Seaquist ER, Anderson J, Childs B et al (2013) Hypoglycaemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36:1384–1395

  5. 5.

    Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA (2012) T1D exchange clinic network. The T1D exchange clinic registry. J Clin Endocrinol Metab 97:4383–4389

  6. 6.

    The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986

  7. 7.

    MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10:238–245

  8. 8.

    Cryer PE, Davis SN, Shamoon H (2003) Hypoglycaemia in diabetes. Diabetes Care 26:1902–1912

  9. 9.

    Leese GP, Wang J, Broomhall J et al (2003) DARTS/MEMO collaboration. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26:1176–1180

  10. 10.

    Geller AI, Shehab N, Lovegrove MC et al (2014) National estimates of insulin related hypoglycaemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 174:678–686

  11. 11.

    Pontiroli AE, Miele L, Morabito A (2012) Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 14:433–446

  12. 12.

    Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347:f4533

  13. 13.

    Berra C, De Fazio F, Azzolini E et al (2019) Hypoglycemia and hyperglycemia are risk factors for falls in the hospital population. Acta Diabetol 56(8):931–938

  14. 14.

    Shalimova A, Graff B, Gasecki D et al (2019) Cognitive dysfunctions in type 1 diabetes. J Clin Endocrinol Metab 104:2239–2249

  15. 15.

    Clarke WL, Gonder-Frederick A, Snyder AL, Cox DJ (1998) Maternal fear of hypoglycaemia in their children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 11(Suppl. 1):189–194

  16. 16.

    Patton SR, Dolan LM, Henry R, Powers SW (2007) Parental fear of hypoglycaemia: young children treated with continuous subcutaneous insulin infusion. Pediatr Diabetes 8:362–368

  17. 17.

    American Diabetes Association (2019) Children and adolescents: standards of medical care in diabetes-2019. Diabetes Care 42(Supplement 1):S148–S164

  18. 18.

    Boido A, Ceriani V, Pontiroli AE (2015) Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol 52:405–412

  19. 19.

    Pontiroli AE, Alberetto M, Pozza G (1983) Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J (Clin Res Ed) 287:462–463

  20. 20.

    Pontiroli AE, Alberetto M, Pozza G (1985) Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection. Acta Diabetol Lat 22:103–110

  21. 21.

    Pontiroli AE, Alberetto M, Calderara A, Pajetta E, Pozza G (1989) Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents. Eur J Clin Pharmacol 37:427–430

  22. 22.

    Slama G, Alamowitch C, Desplanque N, Letanoux M, Zirinis P (1990) A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon. Diabetologia 33:671–674

  23. 23.

    Teshima D, Yamauchi A, Makino K et al (2002) Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int J Pharm 233:61–66

  24. 24.

    Pontiroli AE, Calderara A, Pajetta E, Alberetto M, Pozza G (1989) Intranasal glucagon as remedy for hypoglycaemia. Studies in healthy subjects and type I diabetic patients. Diabetes Care 12:604–608

  25. 25.

    Slama G, Reach G, Cahane M, Quetin C, Villanove-Robin F (1992) Intranasal glucagon in the treatment of hypoglycaemic attacks in children: experience at a summer camp. Diabetologia 35:398

  26. 26.

    Rosenfalck AM, Bendtson I, Jørgensen S, Binder C (1992) Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin dependent) diabetic patients. Diabetes Res Clin Pract 17:43–50

  27. 27.

    Stenninger E, Aman J (1993) Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:931–935

  28. 28.

    Yanai O, Pilpel D, Harman I, Elitzur-Leiberman E, Phillip M (1997) IDDM patients’ opinions on the use of Glucagon Emergency Kit in severe episodes of hypoglycaemia. Practical Diabetes Int 14:40–42

  29. 29.

    Harris G, Diment A, Sulway M, Wilkinson M (2001) Glucagon administration-underevaluated and undertaught. Pract Diabetes Int 18:22–25

  30. 30.

    Rickels MR, Ruedy KJ, Foster NC et al (2016) T1D exchange intranasal glucagon investigators. Intranasal glucagon for treatment of insulin-induced hypoglycaemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care 39:264–270

  31. 31.

    Sherr JL, Ruedy KJ, Foster NC et al (2016) T1D exchange intranasal glucagon investigators. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care 39:555–562

  32. 32.

    Suico J, Hovelmann U, Zhang S et al (2019) Nasal glucagon: a viable alternative to treat insulin-induced hypoglycemia in adults with type 1 diabetes. Off J ATTD Adv Technol Treat Diabetes A-33:19-0062

  33. 33.

    https://www.ajmc.com/newsroom/fda-approves-eli-lillys-nasal-glucagon-to-treat-severe-hypoglycemia-without-injection. Accessed 29 Aug 2019

  34. 34.

    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097

  35. 35.

    Kim SY, Park JE, Lee YJ et al (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66:408–414

  36. 36.

    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–180

  37. 37.

    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867–872

  38. 38.

    Wilson LM, Castle JR (2018) Stable liquid glucagon: beyond emergency hypoglycemia rescue. J Diabetes Sci Technol 12:847–853

  39. 39.

    Frequency of Carrying Glucagon [Internet] (2015) Glu poll. https://myglu.org/polls/1303. Accessed 16 December 2015

  40. 40.

    Driscoll KA, Volkening LK, Haro H et al (2015) Are children with type 1 diabetes safe at school? Examining parent perceptions. Pediatr Diabetes 16:613–620

  41. 41.

    Yale J, Dulude H, Egeth M et al (2017) Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycaemia rescue: a simulation study. Diabete Technol Ther 19:423–432

  42. 42.

    Seaquist E, Dulude H, Zhang M et al (2018) Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab 20:1316–1320

  43. 43.

    Deeb L, Dulude H, Guzman C et al (2018) A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycaemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes 19:1007–1013

  44. 44.

    Settles J, Child CJ, Bajpal SK, Spaepen E, Suico JG (2019) Nasal vs. injected glucagon: user experience results of a simulated severe hypoglycemia study. Diabetes 68(Suppl 1):13LB

  45. 45.

    Guzman C, Dulude H, Piché C et al (2018) Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: a randomized clinical trial. Diabetes Obes Metab 20:646–653

  46. 46.

    Hvidberg A, Djurup R, Hilsted J (1994) Glucose recovery after intranasal glucagon during hypoglycaemia in man. Eur J Clin Pharmacol 46:15–17

  47. 47.

    Liu J, Mitchell B, Bispham J, Fan L, Hughes A, Mcauliffe-Fogarty A (2019) Factors associated with fear of hypoglycemia among the T1D exchange glu population. Diabetes 68(Suppl 1):10LB

Download references

Acknowledgements

This study was supported by a Grant “Ricerca Corrente” to IRCCS Istituto MultiMedica from Ministero della Salute (Ministry of Health), Italy.

Author information

AEP and ET planned the research, searched the data, prepared the database, and contributed to analysis; ET performed the statistical analysis and contributed to discussion; and AEP and ET wrote the manuscript.

Correspondence to Antonio E. Pontiroli.

Ethics declarations

Conflict of interests

The authors declare that they have no conflict of interest.

Ethics approval and consent to participate

This study represents a meta-analysis of studies published. Ethics approval and consent to participate do not apply to this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Managed by Massimo Federici.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 290 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pontiroli, A.E., Tagliabue, E. Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis. Acta Diabetol (2020). https://doi.org/10.1007/s00592-020-01483-y

Download citation

Keywords

  • Hypoglycemia
  • Nasal glucagon
  • Meta-analysis
  • Glucagon
  • Type 1 diabetes
  • Insulin